Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab

被引：0
|
作者：
Orfanoudaki, E. [1 ]
Gazouli, M. [2 ]
Foteinogiannopoulou, K. [1 ]
Theodoraki, E. [1 ]
Legaki, E. [2 ]
Koutroubakis, I. [1 ]
机构：
[1] Univ Hosp Heraklion, Gastroenterol, Iraklion, Crete, Greece
[2] Natl & Kapodistrian Univ Athens, Dept Basic Med Sci, Lab Biol, Athens, Greece
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P408
引用
收藏
页码：S375 / S376
页数：2
相关论文
共 50 条
  • [41] Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease
    Papamichael, Konstantinos
    Vajravelu, Ravy K.
    Osterman, Mark T.
    Cheifetz, Adam S.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (03) : 761 - 767
  • [42] Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease
    Konstantinos Papamichael
    Ravy K. Vajravelu
    Mark T. Osterman
    Adam S. Cheifetz
    Digestive Diseases and Sciences, 2018, 63 : 761 - 767
  • [43] Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
    Lee, Ji Min
    Kim, Yoon Jae
    Lee, Kang-Moon
    Yoon, Hyuk
    Lee, Bo-In
    Kim, Dae Bum
    Kang, Donghoon
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2018, 53 (10-11) : 1280 - 1285
  • [44] Increasing treatment time on REMICADE® (infliximab) predicts subsequent long-term retention in stable infliximab inflammatory bowel disease patients in Canada
    Marshall, J. K.
    Marrache, A. M.
    Ewara, E.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S272 - S273
  • [45] Secondary Non-Immune Loss of Response to Long Term Maintenance Therapy With Infliximab for Inflammatory Bowel Disease is Not Due to Inadequate Trough Levels
    Farber, Michael J.
    Kohn, Nina
    Chua, Vincent
    Sultan, Keith S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S642 - S643
  • [46] Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
    Vande Casteele, Niels
    Ferrante, Marc
    Van Assche, Gert
    Ballet, Vera
    Compernolle, Griet
    Van Steen, Kristel
    Simoens, Steven
    Rutgeerts, Paul
    Gils, Ann
    Vermeire, Severine
    GASTROENTEROLOGY, 2015, 148 (07) : 1320 - +
  • [47] Serum infliximab and antibodies to infliximab levels in Crohn's disease and ulcerative colitis patients on long-term maintenance therapy
    Waterman, M.
    Bar Yoseph, H.
    Ungar, B.
    Ben-Horin, S.
    Chowers, Y.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S357 - S357
  • [48] Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy
    Cao, Wan-Ting
    Huang, Rong
    Liu, Shan
    Fan, Yi-Hong
    Xu, Mao-Sheng
    Xu, Yi
    Ni, Hui
    WORLD JOURNAL OF GASTROENTEROLOGY, 2022, 28 (23) : 2582 - 2596
  • [49] Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn's disease under infliximab therapy
    Wan-Ting Cao
    Rong Huang
    Shan Liu
    Yi-Hong Fan
    Mao-Sheng Xu
    Yi Xu
    Hui Ni
    World Journal of Gastroenterology, 2022, 28 (23) : 2582 - 2596
  • [50] Infliximab Trough Levels Are Associated With Transmural Sonographic Healing in Inflammatory Bowel Disease
    Vaughan, Rose
    Murphy, Elise
    Nalder, Michelle
    Gibson, Robert N.
    Ardalan, Zaid
    Boussioutas, Alex
    Christensen, Britt
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (07) : 1080 - 1088
12345